Objetivo: analizar el sentido de coherencia y su relación con el estilo de vida promotor de salud en estudiantes de una universidad pública en Sonora, México.Metodología: estudio descriptivo y correlacional, participaron 44 estudiantes de las carreras de ciencias de la computación, física y geología. Se empleó una cédula de datos sociodemográficos, la Escala Sentido de Coherencia 13 y el Cuestionario Estilo de Vida II. Se efectuó análisis de datos con medidas de tendencia central y de dispersión, se utilizó el test chi-cuadrado y coeficiente de correlación de Spearman, con un nivel de significancia de alfa 0.05.Resultados: la edad promedio de los estudiantes fue de 20 años, 70,5% eran hombres y solteros, un 52,3% mostró sentido de coherencia global bajo predominando en hombres (54,8%). Un 56,8% obtuvo un estilo de vida promotor de salud insuficiente, mayormente en mujeres (69,2%). El sentido de coherencia tuvo correlación positiva significativa con el estilo de vida promotor de salud (p < 0,05).Conclusiones: la etapa de transición a la vida universitaria es un período importante y crítico para los estudiantes, es prioritario establecer programas de promoción y educación para la salud con enfoque salutogénico, con el propósito de fortalecer el uso de los recursos disponibles y desarrollar un sentido de coherencia más fuerte en los estudiantes, fomentando un estilo de vida promotor de salud permanente.

BackgroundEpidemiology and the reporting characteristics of systematic reviews (SRs) and meta-analyses (MAs) are well known. However, no study has analyzed the influence of protocol features on the probability that a study’s results will be finally reported, thereby indirectly assessing the reporting bias of International Prospective Register of Systematic Reviews (PROSPERO) registration records.ObjectiveThe objective of this study is to explore which factors are associated with a higher probability that results derived from a non-Cochrane PROSPERO registration record for a systematic review will be finally reported as an original article in a scientific journal.Methods/designThe PROSPERO repository will be web scraped to automatically and iteratively obtain all completed non-Cochrane registration records stored from February 2011 to December 2017. Downloaded records will be screened, and those with less than 90% fulfilled or are duplicated (i.e., those sharing titles and reviewers) will be excluded. Manual and human-supervised automatic methods will be used for data extraction, depending on the data source (fields of PROSPERO registration records, bibliometric databases, etc.). Records will be classified into published, discontinued, and abandoned review subgroups. All articles derived from published reviews will be obtained through multiple parallel searches using the full protocol “title” and/or “list reviewers” in MEDLINE/PubMed databases and Google Scholar. Reviewer, author, article, and journal metadata will be obtained using different sources. R and Python programming and analysis languages will be used to describe the datasets; perform text mining, machine learning, and deep learning analyses; and visualize the data. We will report the study according to the recommendations for meta-epidemiological studies adapted from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for SRs and MAs.DiscussionThis meta-epidemiological study will explore, for the first time, characteristics of PROSPERO records that may be associated with the publication of a completed systematic review. The evidence may help to improve review workflow performance in terms of research topic selection, decision-making regarding team selection, planning relationships with funding sources, implementing literature search strategies, and efficient data extraction and analysis. We expect to make our results, datasets, and R and Python code scripts publicly available during the third quarter of 2018.

BackgroundIn the current treatment of Non-Hodgkin’s lymphomas (NHLs) with high-dose methotrexate, the dose is calculated according to different protocols, regardless of patients’ pharmacokinetic variability.PurposeTo evaluate the variability of exposure to methotrexate in adult patients with NHL who received high-dose methotrexate (>1,000 mg/m²) in order to justify the need to individualise the dose and optimise the treatment.Material and methodsRetrospective observational study, between October 2007 and June 2014. We included 43 adult patients (27–77 years old) with NHLs who received 96 cycles of methotrexate. Patients were classified into two groups, patients who received 1,000 mg/m² over 24 h in accordance with the HYPERCYVAD protocol (group I) and those who received 1,500 mg/m² infused over 24 h, following the BURKIMAB-08 protocol (group II). Methotrexate was measured by a fluorescence polarisation immunoassay (TDx/FLx System) in plasma samples obtained at 2, 12, 23, 36, 42 and 60 h after the start of infusion. Methotrexate pharmacokinetics parameters were estimated by Nonlinear Least Squares Regression (software Abbott PKs). The target range of exposure was defined as ±20% of the average AUC value, considering the extreme values positioned outside ±40%.ResultsIn group I, the AUC was 471.05 ± 188.59 μM h (235.29–1,231.34), 52.18% of the patients showed values within the pre-specified target (376.84–565.26), and 21.74% showed extreme values (>659.47 and <282.63). In group II, the AUC was 560.77 ± 194.63 μM h (308.53–1,414.62); 58% of patients showed values within the pre-specified target (448.62–672.93), and 16% showed extreme values (>785.08 and <336.46). The variability of the clearance in these patients (90.04 ± 30.59 ml/min/m²) would explain these results.ConclusionThe variability of exposure to methotrexate (37.99%) justifies the need to individualise dosage to optimise treatment. This could prevent an extreme risk of inefficacy or toxicity in the 18.75% of patients who are outside the pre-specified target range.References and/or acknowledgementsNo conflict of interest.